Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Thermo Fisher sepsis test focus of Fujirebio license agreement
January 2013
SHARING OPTIONS:

WALTHAM, Mass.óThermo Fisher Scientific Inc. and Fujirebio Diagnostics Inc. have inked a long-term license agreement to make Thermo Fisher Scientific's test for the early detection of sepsis available on the latter's laboratory instruments, namely its Lumipulse product line. The sepsis test, the PCT assay, is available worldwide on laboratory instruments from a range of strategic license partners. Financial details and additional terms were not disclosed.

"This agreement with Fujirebio ensures that PCT testing will be available to a much broader patient base, helping to improve patients' outcome," Marc Tremblay, president of Thermo Fisher Scientific's Clinical Diagnostics business, said in a press release. "Through the earlier detection of sepsis, healthcare providers can offer much better treatment to their patients and also achieve dramatic cost savings."

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.